DekaBank Deutsche Girozentrale lifted its stake in shares of Stryker Co. (NYSE:SYK) by 53.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 346,707 shares of the medical technology company’s stock after buying an additional 120,280 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Stryker were worth $70,471,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Advisory Services Network LLC lifted its stake in Stryker by 14.2% during the 2nd quarter. Advisory Services Network LLC now owns 17,130 shares of the medical technology company’s stock valued at $3,523,000 after acquiring an additional 2,126 shares in the last quarter. Coastal Investment Advisors Inc. grew its holdings in Stryker by 29.9% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,008 shares of the medical technology company’s stock valued at $207,000 after buying an additional 232 shares in the last quarter. TD Asset Management Inc. grew its holdings in Stryker by 1.9% during the 2nd quarter. TD Asset Management Inc. now owns 700,140 shares of the medical technology company’s stock valued at $143,935,000 after buying an additional 12,868 shares in the last quarter. Westpac Banking Corp grew its holdings in Stryker by 7.6% during the 2nd quarter. Westpac Banking Corp now owns 88,511 shares of the medical technology company’s stock valued at $18,196,000 after buying an additional 6,246 shares in the last quarter. Finally, Charter Trust Co. grew its holdings in Stryker by 3.3% during the 2nd quarter. Charter Trust Co. now owns 2,220 shares of the medical technology company’s stock valued at $456,000 after buying an additional 70 shares in the last quarter. Institutional investors own 73.48% of the company’s stock.
In other news, Director Allan C. Golston sold 3,399 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $209.84, for a total value of $713,246.16. Following the sale, the director now directly owns 13,762 shares of the company’s stock, valued at $2,887,818.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $214.16, for a total value of $578,232.00. Following the completion of the sale, the chief financial officer now directly owns 20,633 shares in the company, valued at $4,418,763.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,097 shares of company stock worth $4,045,678. Insiders own 7.20% of the company’s stock.
NYSE SYK opened at $219.11 on Wednesday. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $222.59. The stock has a market capitalization of $81.66 billion, a PE ratio of 29.97, a P/E/G ratio of 2.66 and a beta of 0.85. The business has a fifty day moving average of $210.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.26 and a current ratio of 2.07.
Stryker (NYSE:SYK) last released its earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.60 billion. During the same period in the prior year, the firm posted $1.76 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. As a group, equities research analysts expect that Stryker Co. will post 8.2 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.52 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s dividend payout ratio is currently 28.45%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.